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Abstract  
Hypereosinophilic syndrome (HES) is a rare disorder characterized by persistent and 
marked eosinophilia. Some HES forms have a poor prognosis, either because of end-organ 
damage (particularly endomyocardial fibrosis), or because of associated myeloid leukemia or 
malignant T-cell lymphoma. Oral mucosa ulcerations can be early clinical signs in severe forms.  
They are discrete, round or oval, sometimes confluent ulcers or erosions, located on 
non-keratinized, unattached oral mucosa. 
In the last fifteen years a better understanding of eosinophil biology has led to a new 
clinical classification of HES. The lymphocytic form is characterized by T-lymphocyte clonality, 
IL-5 production and a possible progression to T-cell lymphoma. Oral lesions are more frequently 
associated with the myeloproliferative form, characterized by an increased risk of developing 
myeloid malignancies and a good response to a recent anti-tyrosine-kinase therapy (imatinib 
mesylate). Imatinib’s target is a novel kinase resulting from a 800kb deletion on chromosome 4. 
Recently, the resulting FIP1L1-PDGFRα fusion gene was characterized as a marker of response 
to imatinib. 
Exclusion of other erosive-ulcerative oral disease and early recognition of HES in 
patients with oral ulcerations, and precise characterization of the lymphocytic or 
myeloproliferative form, are therefore important to rapidly initiate an effective therapy. 
 
Introduction 
Hypereosinophilic syndrome (HES) is a disorder characterized by persistent and marked 
eosinophilia complicated with end-organ damage (Hardy and Anderson, 1968). Some HES forms 
have a poor prognosis, either because of an eosinophilic myocarditis followed by endomyocardial 
fibrosis, or because of an associated myeloid leukemia or malignant T cell lymphoma (Cogan et 
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al., 1994; Roufosse et al., 2000; Simon et al., 1999).  
Oral mucosa ulcerations, when present, have been reported to be associated with severe forms 
of HES, and can be a presenting feature (Aractingi et al., 1996; Barouky et al., 2003; Billon et al., 
1997; Leiferman et al., 1982). Their precise characterization is important for early diagnosis and 
treatment, more especially as recent therapeutic advances have changed the prognosis of HES 
associated to myeloid proliferations.  
 
Diagnostic criteria for Hypereosinophilic syndrome 
Hardy and Anderson proposed for the first time in 1968 the concept of hypereosinophilic 
syndrome (HES). Diagnostic criteria of idiopathic HES were proposed in 1975 (Chusid et al., 
1975):  
a. blood eosinophilia (>1500 eosinophils /μL) for more than 6 months; 
b. exclusion of reactive eosinophilia caused by parasitic infections, allergies, eosinophilia 
associated with neoplasia; 
c. evidence of end-organ damage related to hypereosinophilia. 
 
A National Institute of Health (NIH) conference in 1982 defined the clinical spectrum for idiopathic 
HES (Fauci et al., 1982). It was not before 1994 that clonal proliferation of type 2 helper (Th2) T 
cells was reported in HES. The production of interleukine-5 (IL-5), a major mediator for eosinophil 
activation and survival, by the clonal T lymphocytes was further described, validating the concept 
of lymphocytic HES (L-HES) variant (Cogan et al., 1994; Roufosse et al., 2000; Simon et al., 
1999). In 2001, the dramatic response of certain forms of HES to a new drug, imatinib mesylate, a 
tyrosine kinase inhibitor efficient in chronic myeloid leukemia (CML) (Druker et al., 2001) led to a 
better characterization of a myeloid variant of HES (M-HES). A cytogenetic mutational deletion on 
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chromosome 4 is constantly found in this M-HES variant, this deletion being specifically linked to 
tyrosine-kinase activity. Further cytogenetic studies led to the recognition of markers of response 
to imatinib (FIP1-like-1-platelet-derived growth factor receptor-α (FIP1L1-PDGFRA) fusion gene), 
and of resistance to this drug (Thr 674Ile mutation)  (Cools et al., 2003; Gleich et al., 2002; Griffin 
et al., 2003; Pardanani et al., 2003; Wilkins et al., 2005). As a result of the characterization of the 
lymphocytic (L-HES) and myeloproliferative (M-HES) variants of HES (summarized in Table I), the 
field of “idiopathic “HES is now greatly reduced (Ballanger et al., 2006; Gleich and Leiferman, 
2005).  
Clinical variants and outcome  
A new clinical classification of hypereosinophilic syndromes has emerged from recent clinical and 
biological progresses (Gleich and Leiferman, 2005; Gotlib, 2005). 
The myeloproliferative HES variant (M-HES) is more often associated with mucosal ulcerations. It 
predominates in males and is characterized by hepatomegaly and splenomegaly. Blood tests 
show a persistent hypereosinophilia, an increased level of serum tryptase and vitamin B12, an 
altered leukocyte alkaline phosphatase score, chromosomal abnormalities, anemia and/or 
thrombocytopenia, and circulating leukocyte precursors (Klion et al., 2003). The prognosis of the 
M-HES variant is poor, with severe cardiac complications, resistance to steroid therapy, and an 
increased risk of developing myeloid malignancies. Patients with M-HES can develop a blast 
crisis revealing an acute eosinophilic or myeloid leukemia. They can also develop a granulocytic 
sarcoma (Roufosse et al., 2003). 
The lymphocytic HES variant (L-HES) is equally distributed in females and males. Mucosal 
lesions are less frequent than in M-HES. Skin manifestations are pruritus, erythematous, 
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urticaria-like, papules and plaques, erythroderma, and angioedema. Patients rarely develop 
endomyocardial fibrosis. The lungs and the digestive tract can be involved. Clonal T cells, of CD3
−
 
CD4
+
 phenotype, express Th2 cytokines as IL-4, IL-5 and IL-13. These clonal T-cells are often 
detected in patients progressing to T cell lymphomas (Ravoet et al., 2005). 
Mucosal ulcerations are often associated with severe forms of HES with systemic involvement.  
A major complication of severe HES, whatever the form, is endomyocardial fibrosis. It is the late 
stage of cardiac involvement, after early necrotic stage (rarely symptomatic), or thrombotic stage 
(intracavitary thrombi developing along the damaged endocardium) (Desreumaux et al., 1993). In 
the late fibrotic stage with endomyocardial fibrosis, cardiac damage involves atrioventricular 
valves and induces congestive heart failure. Independently from endomyocardial lesions, 
peripheral thromboembolism related to an increased number of blood eosinophils may occur 
(Alter and Maisch, 2006; Mabilat-Pragnon et al., 1997). 
 
Clinical and pathological features of oral lesions in Hypereosinophilic syndrome 
HES is a rare disorder with an estimated incidence rate of 0.5 to 1.0 cases per 100,000 per year. 
In a recent study, emphasis was placed on mucosal ulcerations, considering this variant 
presentation of HES as commonly associated with the genetic change resulting in a 
gain-of-function gene (FIP1L1-PDGFRA), characteristic of patients with M-HES (Hofmann et al., 
2006; Leiferman and Gleich, 2004). 
Cutaneous and mucosal signs occur in 27 to 64% of HES cases (Aractingi et al., 1996; Barouky et 
al., 2003; Kazmierowski et al., 1978; Leiferman et al., 1982). 
HES mucosal lesions can be ulcerations, erosions or aphthous lesions localized on the lips, 
gingival, tongue, palatine or jugal mucosa (Fig 1a). They are characterized by discrete, round or 
oval ulcers, sometimes confluent, located on nonkeratinized, unattached mucosa such as buccal 
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and labial mucosa, sulci, lateral and ventral tongue, soft palate, and oropharynx. Lesions are 
painful and may interfere with eating, speaking, or swallowing. These oral lesions may be 
associated with similar genital mucosa or conjunctival lesions. 
 
Oral ulcerations from HES must be differentiated from ulcerations of other causes, mainly local 
traumas, malignant neoplasms, drug or irradiation–induced ulcerations. More numerous are the 
causes of oral ulcerations associated with systemic diseases: microbial diseases, bullous skin 
diseases, inflammatory bowel diseases and necrotic vasculitis (Scully, 1992a; Scully, 1992b). 
Ulcerated lesions from HES must also be differentiated from aphthae, either simple aphtosis, or 
recurrent aphthous stomatitis, recurrent oral and genital aphthae, and Behçet’s disease. They are 
less difficult to differentiate from secondary complex aphtosis within HIV, Cyclic neutropenia, 
FAPA (fever, aphthous stomatitis, pharyngitis, adenitis), gluten sensitive enteropathy, hematinic 
deficiencies (iron, zinc, folate, vitamin B)  (Letsinger et al., 2005).  
 
On hematoxylin-eosin stain, mucosal lesions contain, under an ulcerated epithelium, a 
polymorphous infiltrate composed of lymphocytes, plasma cells and macrophages, with some 
characteristic eosinophils, with bilobated nucleus and eosinophilic cytoplasm (Fig 1b). A specific 
May-Grünwald-Giemsa stain is required to precisely assess the number of eosinophils and their 
distribution. Moreover, activated eosinophils often degranulate, with specific granules scattered in 
the intercellular space within inflammatory infiltrate. Antibodies directed against eosinophilic 
cationic proteins (eosinophil peroxidase - EPO, major basic protein - MBP, eosinophil cationic 
protein - ECP, eosinophil-derived neurotoxin - EDN) can be used on histological sections in order 
to identify eosinophils and the extracellular granules resulting from eosinophil degranulation (Fig 
1c).  
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Electron microscopic examination (Fig 1 d) can be used to identify eosinophils, and their state of 
degranulation. When intact, they are characterized by cytoplasmic granules with a dense matrix 
and a crystallized central core. When observed at different stages of degranulation, they have an 
inverted density of the central cores of the cytoplasmic granules and a partially dissociated 
cytoplasm (Daneshpouy et al., 2002b; Janin et al., 1996). Eosinophil activation can also lead to 
full cell lysis, with ultrastructural features associating with a necrotic nucleus, a disintegrated 
cytoplasm, and surrounding extracellular free granules (Colombel et al., 1990; Janin et al., 1994). 
The ultimate stage of eosinophil lysis results in the constitution of Charcot-Leyden crystals, with 
characteristic sharp and dense crystal shape (Janin et al., 1992). These Charcot-Leyden crystals 
are particularly resistant. They can be found in the tissue two to three weeks after the eosinophil 
lysis (Janin et al., 1993).  They can also be detected in the blood and body fluids as 
broncho-alveolar lavage or urine (Dubucquoi et al., 1994). 
 
HES pathogenetic mechanisms 
 
1  Eosinophil activation and induction of tissue damage 
The release of cationic proteins through eosinophil degranulation and/or lysis can induce tissue 
damage, as demonstrated in vitro on helminthes and epithelial cells (Jong et al., 1981). In human 
pathology, eosinophil infiltration predominates in mucosa, and eosinophil activation is observed in 
oral and bronchial mucosa of asthmatic patients (Gosset et al., 1995; Tsicopoulos et al., 2000), in 
digestive tract of patients with eosinophilic gastroenteritis (Desreumaux et al., 1996) in both skin 
and duodenal mucosa of patients with dermatitis herpetiformis (Desreumaux et al., 1995). The 
biological signs of eosinophilic activation in the blood are hypodense eosinophils. In the tissues, 
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the pathological signs of eosinophil activation is characterized by the release of cationic proteins, 
the presence of hypodense granules on ultrastructural examination and the synthesis of IL-5. 
 Eosinophil activation is also associated with acute symptoms as flare-ups (Daneshpouy et al., 
2002a; Tillie-Leblond et al., 1998; Vandezande et al., 1999) or early recurrences (Desreumaux et 
al., 1992; Dubucquoi et al., 1995) of inflammatory diseases, microvascular lesions and necrosis 
(Launay et al., 2000; Leiferman, 1991). Release of cationic proteins (ECP and MBP) can also 
lead to lipid membrane disruption and target cell death (Weller, 1994). In Hypereosinophilic 
syndromes, activated eosinophils are observed in early oral ulcerations (Aractingi et al., 1996; 
Leiferman et al., 1982) as in late endomyocardial fibrosis (Janin, 2005). 
 
2  Mechanisms of eosinophil chemotactism and activation 
Eosinophils are derived from myeloid progenitors (granulocyte/erythrocyte/macrophage/ 
megakaryocyte-colony forming unit; GEMM-CFU) in bone marrow, through the action of three 
hematopoietic cytokines, granulocyte/macrophage- colony stimulating factor (GM-CSF), 
interleukin (IL)-3 and IL-5 (Sanderson, 1992). Mature eosinophils are released into the blood 
stream and rapidly migrate towards their target tissues (Mishra et al., 1999; Rothenberg and 
Hogan, 2006; Wardlaw, 1999). In physiological conditions, tissue eosinophils survival is short 
(24-48h) (Leiferman, 1991; Moqbel et al., 1994; Rothenberg, 1998). In pathological conditions 
IL-5 prolongs tissue eosinophil survival (Collins et al., 1995; Matthews et al., 1998). The main 
chemotactic mediators are eotaxin-1, eotaxin-2, eotaxin-3, and IL-5. IL-5 is also a major mediator 
for eosinophil activation and in situ survival (Clutterbuck and Sanderson, 1990; Rothenberg et al., 
1997; Zimmermann et al., 2003). IL-5 can be produced by different cells: lymphocytes, 
mastocytes, basophils and eosinophils themselves (Broide et al., 1992; Lorentz et al., 1999; 
Phillips et al., 2003; Till et al., 1997). T-helper lymphocytes with a cytokine profile type Th2 
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express of IL-5, IL-4 and IL-13. Th2-type of response is linked to hypereosinophilia, high serum 
IgE levels and polyclonal hypergammaglobulinemia (due to polyclonal B-cell activation) (Del 
Prete et al., 1989; Genton et al., 2006). Th2 T cells are found in atopic dermatitis, a common 
chronic dermatitis associated with eosinophilia (Kiehl et al., 2001). Clonal Th2 T cells are found in 
T-cell lymphomas, a major complication of the lymphocytic variant of HES (Kitano et al., 1997).  
In pathological conditions, eosinophilic recruitment, proliferation, and activation can be 
initially induced by an acquired abnormal genetic change of myeloid line (Gotlib et al., 2004; 
Keung et al., 2002).  This takes place in the context of an increased hematopoiesis, and is more 
frequently found in the M-HES variant, associated with myeloproliferative disorders.  
Eosinophil recruitment and activation can also be induced by an overproduction of IL-5, IL-3 and 
GM-CSF (Desreumaux et al., 1998; Pazdrak et al., 1998). This is observed mainly in the L-HES 
variant, as in hypereosinophilia associated with Hodgkin's disease, T-cell lymphomas or solid 
tumors (Bain, 2000; Ionescu et al., 2005). Moreover, autocrine production of IL-5 by the 
eosinophil can contribute to chronic eosinophil infiltration (Desreumaux et al., 1996; Desreumaux 
et al., 1992; Desreumaux et al., 1993; Dubucquoi et al., 1994). 
 
Hypereosinophilic syndrome treatment 
A new therapy is now proposed for different variants of HES, based on clinical and biological data. 
Corticotherapy is a first line therapy. It is an efficient therapy, particularly for mucosal ulcerations, 
when HES has not yet been diagnosed. Topic or systemic steroids efficiently decrease 
eosinophilic activation and tissue recruitment by apoptosis induction (Gleich and Leiferman, 
2005; Roufosse et al., 2003). 
M-HES targeted treatment 
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Imatinib mesylate is a tyrosine kinase inhibitor (initially introduced for the treatment of CML), and 
it is the first choice treatment in M-HES, leading to a dramatic improvement (Gleich et al., 2002). 
Imatinib's target is a novel kinase resulting from a 800 kb deletion on chromosome 4. cDNA 
derived from the fusion gene encoded a novel protein composed of the kinase domain of 
PDGFR-α linked to a previously uncharacterized gene resembling FIP1. This genetic 
rearrangement, initially found in the eosinophilic cell line EOL-1 (human acute myeloid 
(eosinophilic) leukemia, DSMZ ACC 386), was also detected in blood cells from patients with HES 
(Griffin et al., 2003). A recent study of 16 HES patients showed that nine responded to imatinib, 
including all five with the FIP1L1–PDGFRA fusion gene. Furthermore, Ba/F3 (murine pro B cell, 
DSMZ ACC 300) cells expressing FIP1L1–PDGFRA were over 100-times more sensitive to 
imatinib than cells expressing breakpoint cluster region- Abelson (BCR-ABL) (Cools et al., 
2003).  
The second generation of BCR–ABL tyrosine kinase inhibitors is used in imatinib-resistant HES 
(Tauchi and Ohyashiki, 2006). 
Other drugs used in M-HES treatment are hydroxyurea (Coutant et al., 1993; Varon et al., 1986; 
Weller and Bubley, 1994), interferon alpha  (Butterfield, 2005; Weller and Bubley, 1994). If signs 
of malignant transformation are found, chemotherapy  (Tanaka et al., 2006) or hematopoietic 
stem cell transplantation (HSCT) must be initiated  (Fukushima et al., 1995). 
L-HES treatment  
In the lymphocytic variant, steroids are very efficient and are the treatment of choice  (Amano et 
al., 2005; Huntgeburth et al., 2005; Wallen et al., 1991; Weller and Bubley, 1994). IFN-alpha can 
be associated to L-HES treatment (Schandene et al., 1996; Schandene et al., 2000; Yoon et al., 
2000). Other treatments are cyclosporin A  (Nadarajah et al., 1997; Zabel and Schlaak, 1991). If 
signs of malignant transformation are diagnosed, the treatment lines specific for T-cell lymphoma 
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are proposed, with chemotherapy (Cyclophosphamide, Hydroxydoxorubicin, Oncovin, 
Prednisone; CHOP-like regimen)  (Granel et al., 2000) , associated or not with monoclonal 
antibodies  (Pitini et al., 2004; Sefcick et al., 2004), fludarabine, 2-chlorodeoxyadenosine (2-CdA)  
(Jabbour et al., 2005; Ueno et al., 1997). In resistant or recurrent cases, intensive high dose 
chemotherapy followed by HSCT can be used  (Ueno et al., 2002). Recently, a specific targeted 
therapy based on an anti-IL-5 monoclonal antibody mepolizumab  (Garrett et al., 2004; Plotz et al., 
2003; Simon et al., 2005; Sutton et al., 2005; Wilkins et al., 2005) has been proposed. 
 
Conclusion 
The field of “idiopathic hypereosinophilic syndromes” has been consistently reduced due to the 
better understanding of eosinophil biology. The therapeutic indications have also been completely 
changed by the efficiency of imatinib on the myeloproliferative forms of HES. The characterization 
of a fusion gene associated with the kinase target of imatinib offers to the physicians a biological 
marker to recognize patients who could benefit from this targeted therapy. Since oral mucosa 
ulcerations are more often associated to M-HES, and can be a presenting sign, oral physicians 
play a key role in the early recognition of M-HES, a necessary step for an efficient therapy. 
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Figure Legends 
 
Hypereosinophilic Syndrome and oral mucosa lesions clinical and microscopic features 
Figure 1a: clinical aspect of mucosal erosions 
 
1b: histological aspect of the inflammatory infiltrate in the biopsy of a mucosal erosion: large 
number of eosinophils with binucleated nucleus and eosinophilic cytoplasm (arrowheads). Scale 
bar: 50 μm 
 
1c: indirect immunohistochemical staining with an antibody directed against Eosinophil 
Peroxidase (EPO) revealed by alkaline phosphatase labelled secondary antibody: the specific 
staining is found in the cytoplasm of intact eosinophils (arrowheads) as well as in cytoplasmic 
component of altered eosinophils (arrow). Scale bar: 50 μm 
 
1d: ultrastructural aspect of the infiltrate, associating activated eosinophils with cytoplasmic 
granule with inverted density of the central cores (1, arrows), degranulating eosinophil with lytic 
nucleus (2), free extracellular cytoplasmic granules (3) and Charcot-Leyden crystal with 
characteristic crystal shape (4). 
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Table I: Clinical and pathological features of the different forms of HES  
(modified from Gleich and Leiferman, 2005) 
 
HES variants Myeloid 
(M-HES) 
Lymphocytic 
(L-HES) 
Unclassified 
Males 
Mucosal ulcers 
 
Eosinophilic 
endomyocarditis 
 
Splenomegaly 
 
Possible progression 
to myeloproliferative 
disorders 
Males/Females 
Pruritus 
Erythematous papules 
erythroderma 
Urticaria-like plaques 
 
 
 
Possible progression to 
T cell lymphomas 
 
Episodic angioedema 
with eosinophilia 
 
Necrotizing 
eosinophilic vasculitis
 
Immunological 
disorders 
Features 
(clinical and 
pathological) 
 
 
 
 
 
 
 
 
 Blood eosinophilia 
(>1500 eosinophils /μL) 
> 6 months 
 
Raised vitamin B12 
and tryptase serum 
levels 
Bone marrow: CD25+ 
atypical mast cells 
 
FIP1L1-PDGFRA 
gene 
Blood eosinophilia 
(>1500 eosinophils /μL)  
> 6 months 
 
Th2 profile clonal 
T-lymphocyte secretion 
(Interleukin-5 
expression)phenotype 
CD3− CD4+
Blood eosinophilia 
(>1500 eosinophils /μL) 
> 6 months 
 
 
 
 
 
 
Treatment 
 
Imatinib-mesylate 
therapy good 
response 
 
Cortisone Cortisone 
Anti-IL-5 
(mepolizumab) 
IFN 
Hydroxyurea 
Cyclosporin 
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